Company Description
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide.
The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-generating device for fallopian tube diagnosis.
Its product candidate, FemBloc, is a non-surgical permanent birth control solution. It offers its products to reproductive endocrinologists for infertility products, gynecological physicians, related healthcare professionals, and women’s healthcare provider organizations.
Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
| Country | United States |
| Founded | 2004 |
| IPO Date | Jun 18, 2021 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 71 |
| CEO | Kathy Lee-Sepsick |
Contact Details
Address: 3950 Johns Creek Court, Suite 100 Suwanee, Georgia 30024 United States | |
| Phone | 770 500 3910 |
| Website | femasys.com |
Stock Details
| Ticker Symbol | FEMY |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $13.00 |
| CIK Code | 0001339005 |
| CUSIP Number | 31447E105 |
| ISIN Number | US31447E1055 |
| Employer ID | 11-3713499 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Kathy Lee-Sepsick M.B.A. | Founder, President, Chief Executive Officer and Director |
| Dov Elefant | Chief Financial Officer |
| Daniel Scott Currie | Chief Operating Officer, Senior Vice President and Secretary |
| Mary An Merchant J.D., Ph.D. | Vice President of Counsel and Intellectual Property |
| Naomi Phaneuf | Vice President of Marketing |
| Benjamin Dings | Vice President of Sales |
| Dr. Jeffrey Marcus M.D., M.S. | Chief Medical Advisor |
| Christine Thomas | Senior Vice President of Regulatory and Clinical Affairs |
| Dr. James H. Liu M.D. | Chief Medical Officer |
| Richard Spector | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 8-K | Current Report |
| Feb 26, 2025 | SCHEDULE 13G | Filing |
| Feb 26, 2025 | SCHEDULE 13G | Filing |
| Nov 12, 2024 | 8-K/A | [Amend] Current report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |